{"id":"telmisartan-rosuvastatin","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Telmisartan works by blocking the angiotensin II type 1 receptor, which is a key component of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, telmisartan causes vasodilation and reduces blood pressure. Rosuvastatin, on the other hand, works by inhibiting the enzyme HMG-CoA reductase, which is a key step in the biosynthesis of cholesterol. By inhibiting this enzyme, rosuvastatin reduces the production of cholesterol in the liver and increases the clearance of LDL cholesterol from the bloodstream.","oneSentence":"Telmisartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering LDL cholesterol.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:57.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension, Hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT06515652","phase":"NA","title":"To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome","status":"RECRUITING","sponsor":"Hamdard University","startDate":"2023-09-01","conditions":"Metabolic Syndrome","enrollment":200},{"nctId":"NCT03474562","phase":"PHASE4","title":"High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-04-03","conditions":"ASCVD, Impaired Fasting Glucose, Hypertension","enrollment":100},{"nctId":"NCT04158076","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-01-23","conditions":"Hypercholesterolemia, Hypertension","enrollment":131},{"nctId":"NCT03267329","phase":"PHASE4","title":"Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-09-11","conditions":"Hypertension, Dyslipidemia","enrollment":80},{"nctId":"NCT03872232","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2019-02-26","conditions":"Hypercholesterolemia, Hypertension","enrollment":180},{"nctId":"NCT03550859","phase":"PHASE4","title":"HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria","status":"UNKNOWN","sponsor":"Yuhan Corporation","startDate":"2018-06-05","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":374},{"nctId":"NCT04659070","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-07-15","conditions":"Primary Hypercholesterolemia, Hypertension","enrollment":156},{"nctId":"NCT03707899","phase":"PHASE1","title":"The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2018-12-13","conditions":"Hypertension With Dyslipidemia","enrollment":49},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT02968160","phase":"PHASE4","title":"A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Yuhan Corporation","startDate":"2016-10","conditions":"Metabolic Syndrome","enrollment":55},{"nctId":"NCT03860220","phase":"PHASE4","title":"The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin","status":"UNKNOWN","sponsor":"Hyo-Soo Kim","startDate":"2019-03-01","conditions":"Hypertension, Dyslipidemias","enrollment":304},{"nctId":"NCT03116516","phase":"PHASE1","title":"Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-04-21","conditions":"Hypertension, Hyperlipidemia","enrollment":62},{"nctId":"NCT03067688","phase":"PHASE3","title":"Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-04-11","conditions":"Hypertension, Hyperlipidemia","enrollment":202},{"nctId":"NCT03742544","phase":"","title":"Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-06-23","conditions":"Hypertension, Dyslipidemias","enrollment":600},{"nctId":"NCT03088254","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-09-20","conditions":"Dyslipidemia With Hypertension","enrollment":126},{"nctId":"NCT03566316","phase":"PHASE3","title":"Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-11-24","conditions":"Hypertension With Hyperlipidemia","enrollment":134},{"nctId":"NCT03210532","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2016-10-07","conditions":"Hypertension, Dyslipidemia","enrollment":129},{"nctId":"NCT03247140","phase":"PHASE1","title":"The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2017-06-10","conditions":"Hypertension With Dyslipidemia","enrollment":40},{"nctId":"NCT02608242","phase":"PHASE1","title":"PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin","status":"TERMINATED","sponsor":"Yuhan Corporation","startDate":"2015-11","conditions":"Hypertension, Hyperlipidemia","enrollment":123},{"nctId":"NCT02951962","phase":"PHASE1","title":"A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2016-08","conditions":"Hypertension, Hyperlipidemia","enrollment":60},{"nctId":"NCT02933658","phase":"PHASE1","title":"Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2015-11","conditions":"Hypertension and Dyslipidemia","enrollment":71},{"nctId":"NCT02387619","phase":"PHASE1","title":"The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2015-02","conditions":"Hypertension, Hyperlipidemia","enrollment":41},{"nctId":"NCT02233218","phase":"PHASE1","title":"The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2014-07","conditions":"Healthy Male Volunteer","enrollment":60},{"nctId":"NCT01914432","phase":"PHASE3","title":"Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2013-11","conditions":"Hyperlipidemia, Hypertension","enrollment":210},{"nctId":"NCT02047175","phase":"PHASE1","title":"CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-02","conditions":"Hypertension, Hyperlipidemia","enrollment":64},{"nctId":"NCT02087540","phase":"PHASE3","title":"Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-05","conditions":"Hypertension, Hyperlipidemia","enrollment":310},{"nctId":"NCT01992601","phase":"PHASE1","title":"A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2012-11","conditions":"Healthy Volunteer","enrollment":48},{"nctId":"NCT01975961","phase":"PHASE1","title":"PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2013-07","conditions":"Dyslipidemia & Hypertension","enrollment":185}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Telmisartan + Rosuvastatin","genericName":"Telmisartan + Rosuvastatin","companyName":"Daewon Pharmaceutical Co., Ltd.","companyId":"daewon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telmisartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering LDL cholesterol. Used for Hypertension, Hyperlipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}